Pharmacokinetics, Pharmacodynamics, and Safety of Evocalcet (KHK7580), a Novel Calcimimetic Agent: An Open-Label, Single- and Multiple-Dose, Phase I Trial in Healthy Chinese Subjects
Xuemei He,Kazuya Narushima,Masahiro Kojima,Chisato Nagai,Kexin Li
DOI: https://doi.org/10.2147/dddt.s437903
IF: 4.3188
2024-02-26
Drug Design Development and Therapy
Abstract:Xuemei He, 1 Kazuya Narushima, 2 Masahiro Kojima, 2 Chisato Nagai, 2 Kexin Li 1 1 Clinical Trial Center, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application, Beijing, People's Republic of China; 2 Research & Development Division, Kyowa Kirin Co., Ltd, Tokyo, Japan Correspondence: Kexin Li, Clinical Trial Center, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application, Beijing, People's Republic of China, Email Purpose: This study explored the pharmacokinetics (PK), pharmacodynamics (PD), and safety of evocalcet (KHK7580), a new calcimimetic agent, in healthy Chinese subjects following single and multiple doses. Methods: This was a single-center, open-label phase I trial conducted in China. The study started from the single-dose cohorts (1, 3, 6, 12 mg evocalcet, step-by-step administration) and proceeded to the multiple-dose cohort (6 mg evocalcet once daily for eight days). Blood and urine samples were collected at the designated time points for pharmacokinetic and pharmacodynamic analysis. Safety was evaluated by treatment-emergent adverse events (TEAEs), clinical laboratory tests, vital signs, electrocardiograms (ECGs), and ophthalmological examination. Results: Among 42 enrolled subjects, eight in each single-dose cohort and 10 in multiple-dose cohort, 40 subjects completed the study. In single-dose cohorts, t max was 1.00– 2.00 h and declined biphasically. The mean t 1/2 was 15.99– 20.84 h. Evocalcet exposure in AUC 0-inf , AUC 0-t , and C max showed a dose-proportional increase. In the multiple-dose cohort, t max was 2.00 h and declined biphasically after multiple administrations. The accumulation was negligible. C trough levels were similar across days and steady from 24 hours after the first administration. The mean t 1/2 was 15.59 h. PD analysis showed that evocalcet decreased intact parathyroid hormone and corrected calcium levels in a dose-dependent manner. Seventeen (40.5%) subjects reported TEAEs. No serious or severe TEAE occurred. Conclusion: In healthy Chinese subjects, evocalcet demonstrated dose-dependent PK and PD properties and was well-tolerated. Keywords: evocalcet, calcimimetic agents, secondary hypoparathyroidism, pharmacokinetic, pharmacodynamic, safety Chronic kidney disease (CKD)-mineral and bone disorder (MBD) is a systemic disorder of mineral and bone metabolism due to CKD and is associated with common complications such as fragility fractures and vascular and valvular calcification. 1,2 Secondary hyperparathyroidism (SHPT) is one of the most significant types of CKD-MBD, with a prevalence of 11.5%-54%. 3,4 It is characterized by excessive secretion of parathyroid hormone (PTH), hyperphosphatemia, and hypocalcemia, leading to osteitis fibrosis and ectopic calcification, resulting in high morbidity and mortality. 4–6 In China, the prevalence of severe hyperphosphatemia (>7 mg/dL) and SHPT (>600 pg/mL) were 27% and 21% in patients undergoing hemodialysis, respectively. Furthermore, the management of MBD in China requires improvement and standardization. 7 The traditional interventions for SHPT include the modulation of phosphorus (P) and calcium (Ca) balance by dialysis and dietary restriction, calcitriol, other vitamin D analogs, and phosphate binders. 5 Furthermore, serum PTH levels should be lowered to a target range. 8 Calcimimetic agents mimic the action of Ca on calcium-sensing receptors (CaSR) in the parathyroid gland, thus suppressing PTH synthesis and secretion. 9–11 Cinacalcet hydrochloride (the first calcimimetic agent approved for use) and etelcalcetide reduce intact PTH levels and affect P and Ca in CKD patients with SHPT. 9,12,13 Nevertheless, the safety concerns of cinacalcet hydrochloride regarding the upper gastrointestinal tract burden the patients and limit the dosage increase to a thoroughly effective level. 14 In addition, specific considerations for drug interactions are required when coadministered with other drugs because cinacalcet hydrochloride has a strong inhibitory effect on cytochrome P450 (CYP) 2D6 and is metabolized by CYP3A4. 15–17 Unlike cinacalcet, etelcalcetide activates the CaSR by binding the extracellular domain. Etelcalcetide allows better compliance than cinacalcet due to fewer pills to be taken and i -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal